ArticleGeburtshilfe und Frauenheilkunde2023

Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer.

Natalia Krawczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.